Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lisata Therapeutics (LSTA) Net Margin (2016 - 2025)

Lisata Therapeutics' Net Margin history spans 11 years, with the latest figure at 2954.0% for Q4 2025.

  • For Q4 2025, Net Margin fell 249300.0% year-over-year to 2954.0%; the TTM value through Dec 2025 reached 9756.47%, down 775797.0%, while the annual FY2025 figure was 9756.47%, 775797.0% down from the prior year.
  • Net Margin reached 2954.0% in Q4 2025 per LSTA's latest filing, up from 6655.71% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 461.0% in Q4 2024 to a low of 6655.71% in Q2 2025.